Table 6.
Ongoing Trials in Additional PCa Settings
| Study | Setting | Phase | Study Arms | Primary Endpoint | Trial ID Number | Estimated Primary Completion |
|---|---|---|---|---|---|---|
| ARASENS | mCSPC | 3 | ADT+ docetaxel + darolutamide or placebo | OS | NCT02799602 | August 2022 |
| EORTC-1532 | CSPC | 2 | ADT vs darolutamide | PSA response | NCT02972060 | December 2020 |
| SGCCR | mCRPC | 2 | Post-docetaxel maintenance darolutamide vs placebo | RPFS | NCT02933801 | December 2020 |
| ODENZA | mCRPC | 2 | Enzalutamide vs darolutamide | Patient preference | NCT03314324 | January 2022 |
| INTREPId | Localized | 2 | RT + ADT + bicalutamide vs RT = darolutamide | PSA nadir ≤0.5 | NCT04025372 | September 2022 |